Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
What is Atenolol?
What does Atenolol look like?
What are the available doses of Atenolol?
Sorry No records found.
What should I talk to my health care provider before I take Atenolol?
Sorry No records found
How should I use Atenolol?
What interacts with Atenolol?
Sorry No Records found
What are the warnings of Atenolol?
In Patients Without a History of Cardiac Failure
DOSAGE AND ADMNISTRATION
Cessation of Therapy with Atenolol
DOSAGE AND ADMINISTRATION
Concomitant Use of Calcium Channel Blockers
PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta selectivity, however, atenolol may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Since betaselectivity is not absolute, the lowest possible dose of atenolol should be used with therapy initiated at 50 mg and a beta-stimulating agent (bronchodilator) should be made available. If dosage must be increased, dividing the dose should be considered in order to achieve lower peak blood levels.
Anesthesia and Major Surgery
Diabetes and Hypoglycemia
DOSAGE AND ADMINISTRATION
Pregnancy and Fetal Injury
PRECAUTIONS, Nursing Mothers
What are the precautions of Atenolol?
Impaired Renal Function
Carcinogenesis, Mutagenesis, Impairment of Fertility
Usage in Pregnancy
WARNINGS - Pregnancy and Fetal Injury
WARNINGS, Pregnancy and Fetal Injury
Hypertension and Angina Pectoris Due to Coronary Atherosclerosis
Acute Myocardial Infarction
What are the side effects of Atenolol?
Most adverse effects have been mild and transient.
The frequency estimates in the following table were derived from controlled studies in hypertensive patients in which adverse reactions were either volunteered by the patient (US studies) or elicited, e.g., by checklist (foreign studies). The reported frequency of elicited adverse effects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship to atenolol is uncertain.
|Volunteered( )||Total-Volunteeredand Elicited ( )|
|Atenolol(n = 164)%||Placebo(n = 206) %||Atenolol(n = 399) %||Placebo(n = 407) %|
|CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR|
|RESPIRATORY (see WARNINGS)|
Acute Myocardial Infarction
In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta-blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosages of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations is given in the following table.
In a study of 477 patients, the following adverse events were reported during either intravenous and/or oral atenolol administration:
In the subsequent International Study of Infarct Survival (ISIS-1) including over 16,000 patients of whom 8,037 were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons:
During postmarketing experience with atenolol, the following have been reported in temporal relationship to the use of the drug: elevated liver enzymes and/or bilirubin, hallucinations, headache, impotence, Peyronie's disease, postural hypotension which may be associated with syncope, psoriasiform rash or exacerbation of psoriasis, psychoses, purpura, reversible alopecia, thrombocytopenia, visual disturbances, sick sinus syndrome, and dry mouth. Atenolol, like other beta-blockers, has been associated with the development of antinuclear antibodies (ANA), lupus syndrome, and Raynaud’s phenomenon.
|Conventional TherapyPlus Atenolol(n=244)||ConventionalTherapy Alone(n=233)|
|BBB + MajorAxis Deviation||16||(6.6%)||28||(12%)|
|Total Cardiac Arrests||4||(1.6%)||16||(6.9%)|
|Nonfatal Cardiac Arrests||4||(1.6%)||12||(5.1%)|
|Development of VentricularSeptal Defect||0||(0%)||2||(0.9%)|
|Development of MitralRegurgitation||0||(0%)||2||(0.9%)|
|Pulmonary Emboli||3||(1.2%)||0||(0%)||Full dosage was 10 mg and some patients received less than 10 mg but more than 5 mg.||Oral PartialDose|
|Hypotension / Bradycardia||105||(1.3%)||1168||(14.5%)|
|Heart Block (> first degree)||5||(.06%)||143||(1.7%)|
What should I look out for while using Atenolol?
What might happen if I take too much Atenolol?
How should I store and handle Atenolol?
Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature].They are supplied by as follows:This Product was Repackaged By:State of Florida DOH Central PharmacyThey are supplied by as follows:This Product was Repackaged By:State of Florida DOH Central PharmacyThey are supplied by as follows:This Product was Repackaged By:State of Florida DOH Central Pharmacy
Chemical StructureNo Image found
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
ProfessionalClonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
InteractionsA total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).